Status:
UNKNOWN
(Cost)-Effectiveness of Optical Coherence Tomography (OCT) in Basal Cell Carcinoma (BCC)
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
ZonMw: The Netherlands Organisation for Health Research and Development
Conditions:
Basal Cell Carcinoma
Optical Coherence Tomography
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A multi-centre randomized non-inferiority trial investigating the (cost-)effectiveness of Optical Coherence Tomography (OCT) versus regular punch biopsy in the diagnosis and subtyping of Basal Cell Ca...
Detailed Description
Skin cancer incidence rises worldwide due to high sun exposure and ageing. Basal cell carcinoma (BCC) is the most prevalent form, with a lifetime risk of 16-20% in the Netherlands. Currently, the gold...
Eligibility Criteria
Inclusion
- Adult patient (\>18 years)
- Clinical and dermoscopic suspicion of BCC
- BCC is in the differential diagnosis and a biopsy would normally be obtained to confirm the diagnosis and subtype or exclude other skin lesions.
Exclusion
- Patients with BCC in the high-risk zone of the face (ear, nose, eye region)
- Patients with a large BCC referred to our (tertiary care) head and neck tumour working group.
Key Trial Info
Start Date :
February 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
598 Patients enrolled
Trial Details
Trial ID
NCT03848078
Start Date
February 26 2019
End Date
October 1 2021
Last Update
February 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht UMC+
Maastricht, Limburg, Netherlands, 6229 HX